Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Status:
Withdrawn
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This phase II pilot trial studies how well bicalutamide and raloxifene hydrochloride work in
treating patients with prostate cancer undergoing surgery. Antihormone therapy, such as
bicalutamide and raloxifene hydrochloride, may lessen the amount of androgens made by the
body.